A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
for Non-Small Cell Lung Cancer
8 locations incl. Springdale
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT07155187·Phase 2, Phase 3·Recruiting